These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32120027)

  • 1. Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports.
    Fuerte-Hortigón A; López Ruiz R; Hiraldo J; Sánchez Fernández F; Dotor García-Soto J; Páramo MD; Ruiz-Peña JL; Navarro-Mascarell G; Eichau S
    Mult Scler Relat Disord; 2020 Jun; 41():102017. PubMed ID: 32120027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide.
    Robertson D; Dixon C; Aungst A; McCoy B; Moreo N; Casady L; Maldonado J
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1403-1407. PubMed ID: 29064296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
    Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    Yamout BI; Said M; Hannoun S; Zeineddine M; Massouh J; Khoury SJ
    J Neurol Sci; 2017 Sep; 380():79-81. PubMed ID: 28870594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teeth loss after teriflunomide treatment: Casual or causal? A short case series.
    Vacchiano V; Frattaruolo N; Mancinelli L; Foschi M; Carotenuto A; Scandellari C; Piattelli M; Brescia Morra V; Lugaresi A
    Mult Scler Relat Disord; 2018 Aug; 24():120-122. PubMed ID: 29982109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
    Freedman MS; Wolinsky JS; Comi G; Kappos L; Olsson TP; Miller AE; Thangavelu K; Benamor M; Truffinet P; O'Connor PW;
    Mult Scler; 2018 Apr; 24(4):535-539. PubMed ID: 28304217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
    Sartori A; Carle D; Freedman MS
    Expert Opin Pharmacother; 2014 May; 15(7):1019-27. PubMed ID: 24742277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
    Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
    BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study.
    Condé S; Moisset X; Pereira B; Zuel M; Colamarino R; Maillet-Vioud M; Lauxerois M; Taithe F; Clavelou P;
    Eur J Neurol; 2019 Mar; 26(3):460-467. PubMed ID: 30320947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriflunomide: a review of its use in relapsing multiple sclerosis.
    Garnock-Jones KP
    CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Son M; McEwan L; Ubaidat M; Bovell K; Morrow SA
    Mult Scler; 2020 Nov; 26(13):1801-1803. PubMed ID: 32031458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
    Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
    Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
    Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
    Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
    Chan A; de Seze J; Comabella M
    CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.